Evidence map›Paper›PMID 41631000›Full record

ArticleAmerican heart journal plus : cardiology research and practice2026

Predicting cardiovascular diseases using imbalanced data: An XGBoost-based analysis of the 2022 BRFSS dataset.

Masoud Imani, Ali Maroosi, Seyedshayan Shojaei, Kimia Heidari, Seyed Mahdi Hoseinzadeh, Nima Daneshi, Zahra Saber, Negar Sajadi, Morteza Mohammadzadeh

Abstract read
In one paragraph

Article in American heart journal plus : cardiology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Masoud ImaniStudent Research Committee, Iran University of Medical Sciences, Tehran, Iran.
Ali MaroosiDepartment of Biostatistics, School of Public Health, Mazandaran University of Medical Sciences, Sari, Iran.
Seyedshayan ShojaeiWestern University of Health Sciences, College of Osteopathic Medicine of the Pacific, Pomona, CA, USA.
Kimia HeidariUniversity of California, Irvine, School of Medicine, Irvine, CA, USA.
Seyed Mahdi HoseinzadehDepartment of Biostatistics, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran.
Nima DaneshiDepartment of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
Zahra SaberDepartment of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
Negar SajadiInternal Medicine Resident, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Morteza MohammadzadehDepartment of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide, arising from complex interactions among demographic, clinical, behavioral, and social determinants. Leveraging large, nationally representative datasets such as the 2022 Behavioral Risk Factor Surveillance System (BRFSS) offers a unique opportunity to identify emerging risk patterns, monitor population-level disparities, and inform more targeted prevention strategies. Methods: A total of 221,643 participants from the BRFSS 2022 survey were included after excluding records with missing data. Thirteen key predictors spanning demographics, chronic conditions, and social factors were selected. Data were split into training (80%) and testing (20%) sets. Four machine learning models, XGBoost, Random Forest, Logistic Regression, and Naive Bayes, were developed and evaluated using stratified 10-fold cross-validation. Model performance was assessed via accuracy, F1 score, precision, sensitivity, and ROC AUC. Synthetic Minority Over-sampling Technique (SMOTE) addressed class imbalance. SHAP values provided insights into feature importance and model interpretability. Results: XGBoost demonstrated the best predictive performance (accuracy 94.2%, F1 score 85.3%, ROC AUC 0.94). SHAP analysis highlighted age ≥ 65, male gender, and diabetes as the strongest predictors, with additional contributions from kidney disease, employment status, and social isolation. Protective effects were observed for never smoking and higher education. Stratified analyses revealed that while overweight/obesity (BMI ≥25) was generally associated with higher CVD prevalence, the association was attenuated in older adults, smokers, and those with diabetes or kidney disease, suggesting illness-related weight loss, frailty, and behavioral confounding. These subgroup insights contextualize the apparent "BMI paradox" observed in the aggregate data. Conclusions: Findings from the BRFSS 2022 highlight both established and emerging determinants of CVD risk, including the modifying effects of comorbidities, social isolation, and BMI-related heterogeneity. Beyond algorithmic performance, these results underscore the value of national surveillance data for informing applied, actionable strategies in CVD prevention and risk stratification.

Indexed as

BRFSSCardiovascular diseaseMachine learningPredictive modelingSHAP analysisXGBoost

Identifiers

PMID41631000
PMCPMC12860618

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.